A decade of clinical data with vedolizumab: the past, present, and future.

Ther Adv Gastroenterol · 2026 · PMC13201942 · PMID 42205859

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Highly significant differences in measured VDZ exposure were predicted by the CDST-defined response categories throughout the 52-week study, irrespective of when VDZ exposure was measured.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.